The Cancer Terminator Foundation is Introducing a Revolutionary Cancer Cure to America

“The world’s leading 40 scientists and physicians specializing in advanced Heavy-Ion Therapy have come together to create the Cancer Terminator Foundation.

 

Although developed in the United States, Heavy-Ion Therapy is not available here due to high construction costs. An unprecedented group effort has now begun to make Heavy-Ion Therapy available to patients in America. With the help of Breakthrough Chronic Care, we are committed to building several Heavy-Ion Therapy machines in the United States in the coming years. And, providing treatment for children and Veterans in Vienna, Austria... exciting times.”

Steven J. Frank, MD

Co-Chairman, Cancer Terminator Foundation. Medical Director, Director of Advanced Technologies, MD Anderson Cancer Center.

Unprecedented Cure Rates Today!

Brain tumors and tumors at the base of the skull have achieved a 90% five-year survivor rate. 

 

Advanced pancreatic cancer results show a two-year survival rate of nearly 50%, with only 5% from traditional treatments. 

 

Inoperable chordomas achieve an 85% survival rate, which is better than patients who had tumors surgically removed. 

 

50% to 80% cure rates are achieved by treating late-stage prostate, liver, rectal, lung cancers and advanced bone and soft tissue sarcomas which, up until now, have been radiation-resistant. 

 

Preliminary results in treating advanced colon, breast cancer, and additional cancers are extremely positive.

 

50% cure rate, or higher, for inoperable spinal tumors and various tumors including adenocarcinoma, adenoid cystic carcinoma, and malignant melanoma that were completely resistant to previous therapy options.

Heavy-Ion Therapy destroys cancer tumor cells more effectively than any other cancer treatment available today

Heavy-Ion Therapy employs supercharged rays that are focused with high precision at a deep tumor resulting in its destruction. 

The therapy shatters cancer’s DNA (at more than 75% of light speed) leaving it unable to reproduce. Precise pinpoint-targeting limits the effects to the cancer cell leaving surrounding healthy tissue and organs intact. Thus, we can now destroy deep cancer tumors that were previously unreachable with fewer long-term effects. While standard therapy often requires 35 sessions over three months, Heavy-Ion Therapy often only requires four sessions over two weeks. Fewer treatments dramatically reduce suffering. Over 20,000 patients have been treated with the first generation Heavy-Ion Therapy in Japan and Europe with unprecedented cure rates.

The Cancer Terminator Foundation Arranges Free Heavy-Ion Therapy in Vienna, Austria for American Children and Veterans.

The Cancer Terminator Foundation proudly announces that in 2020 they will provide the first Texas child with inoperative sarcoma cancer the breakthrough treatment of Heavy-Ion Therapy. In addition, they will provide Veterans Heavy-Ion Therapy. Heavy-Ion Therapy is not yet available in the United States. The Cancer Terminator Foundation will send patients to MedAustron Clinic in Vienna, Austria.

Prof. Dr. Eugen B. Hug

Co-Chairman, Cancer Terminator Foundation. Medical Director, MedAustron Ion Therapy Center, Vienna, Austria. Pioneer in Heavy-Ion Technologies.

“The MedAustron Therapy Center in Vienna, Austria, is excited about the partnership with the Cancer Terminator Foundation to start treating American children and Veterans with this groundbreaking therapy. American patients don’t need to wait; we will work closely with the Cancer Terminator Foundation to provide immediate access to those in need. I am a co-founder of the Cancer Terminator Foundation, and this is an important part of our mission.

 

We have used the first generation Heavy-Ion Therapy successfully with over 8,000 patients. Up to now, the MedAustron Therapy Center has concentrated on treating brain tumors, tumors of the skull base or the spinal cord, pediatric cancers, and prostate cancer. We plan to expand the range of treatments in the upcoming years. We thank Breakthrough Chronic Care for helping us on our journey.”

“Breakthrough Chronic Care is committed to helping the Cancer Terminator Foundation raise $1.5 billion dollars to build Heavy Ion Therapy machines in the United States and sending American children and Veterans to MedAutron Clinic in Vienna, Austria for immediate treatment. 

 

We are working on a five-year plan to build several Heavy-Ion Therapy machines  so every American who needs treatment will have access whether they are a Breakthrough Chronic Care patient or not.”

Jerry Woloszczuk

Co-Founder, CFO Breakthrough Chronic Care

Breakthrough Chronic Care is the original financial donor that made the Cancer Terminator Foundation possible. We work closely with the Foundation and it's Scientific Advisory Board. We provide ongoing financial support.

Oren Cahlon, MD. Physician-in-Chief, Radiation Oncology, Sloan Kettering Cancer Center joins the Cancer Terminator Foundation Scientific Advisory Board

“Memorial Sloan Kettering has been at the forefront of cancer treatments. The Cancer Terminator Foundation and Heavy-Ion therapy is exactly that. Dr. Hug, Dr. Frank, and our esteemed Scientific Advisory Board can accomplish significant advances in the successful treatment of late-stage cancers. Breakthrough Chronic Care has been instrumental in our development.” 

Oren Cahlon, MD, is a board-certified radiation oncologist whose clinical practice is primarily focused on breast cancer. As part of a multi-disciplinary team of breast cancer experts, he works to identify the optimal treatment approach for each patient. 

Anita Mahajan, MD, Radiation Oncologist at the Mayo Clinic, Joins the Cancer Terminator Foundation’s Scientific Advisory Board

“Heavy-Ion protons provide effective cancer-killing power, with less collateral damage to adjacent tissues. We need to bring Heavy-Ion Therapy to American now, and I am happy to join the Cancer Terminator Foundation’s Scientific Advisory Board to help make this happen. We thank Breakthrough Chronic Care for their support.”

Anita Mahajan, MD, is a radiation oncologist in Rochester, Minnesota and is a member of the group practice Mayo Clinic. She is also affiliated with Memorial Hermann Texas Medical Center and University Of Texas MD Anderson Cancer Center. She received her medical degree from McGill University in Montreal, Quebec, Canada, where she also completed an internship in internal medicine and a residency in radiation oncology.

Michael P. Hagan, MD, PhD, Chairman of Radiation Oncology at the Department of Veterans Affairs, Joins the Scientific Advisory Board for the Cancer Terminator Foundation.

“Memorial Sloan Kettering has been at the forefront of cancer treatments. The Cancer Terminator Foundation and Heavy-Ion therapy is exactly that. Dr. Hug, Dr. Frank, and our esteemed Scientific Advisory Board can accomplish significant advances in the successful treatment of late-stage cancers. Breakthrough Chronic Care has been instrumental in our development.” 

Michael P. Hagan, MD, is a Radiation Oncology specialist in Richmond, Virginia. He attended and graduated from Baylor College Of Medicine in 1989, having over 30 years of diverse experience, especially in Radiation Oncology. He is affiliated with many hospitals including Medical College Of Virginia Hospitals. He has extensive laboratory research experience involving the effects of irradiation on biological systems.

Bhadrasain Vikram, MD, Chief of Clinical Radiation Oncology at the National Cancer Institute joins the Cancer Terminator Foundation Scientific Advisory Board. 

“The National Cancer Institute believes Heavy-Ion is the next generation in curing several cancers that are untreatable today. I look forward to working with Dr. Frank and Dr. Hug in providing it to as many patients as possible. Our mission is critical and the Cancer Terminator Foundation will play a vital role. We appreciate Breakthrough Chronic Care for helping to make it a reality.”

Bhadrasain Vikram, MD,  received his medical degree from the University of Delhi and trained in radiation oncology at Memorial Sloan-Kettering Cancer Center in New York City. He subsequently served on the faculties of Memorial Sloan-Kettering, Cornell University Medical College and Mount Sinai School of Medicine. He has authored over 150 scientific publications and was listed as among the 1000 ‘Best Doctors in America’ by American Health magazine, a Reader’s Digest publication.

Quynh-Thu Le, MD, Chair, Department of Radiation Oncology, Stanford University, Joins the Cancer Terminator Foundation Scientific Advisory Board. 

“Heavy-Ion Therapy is a major advance for treating several cancers. Stanford worked with the VA to bring it to America with no success. The Cancer Terminator Foundation is changing this. Providing children and Veteran cancer patients immediate free treatment with Dr. Hug in Vienna, Austria is lifesaving. Breakthrough Chronic Care’s support in helping to create the Cancer Terminator Foundation is greatly appreciated.”

Quynh-Thu Le, MD received both her medical school and radiation oncology training at the University of California, San Francisco (UCSF). She then joined the Stanford faculty in 1997. She became the Chair of the Stanford Radiation Oncology Department in September 2011. Stanley Memorial Professorship at Stanford University.

Dr. Robert L. Foote, MD, Chairman of Radiation Oncology at the Mayo Clinic Joins the Cancer Terminator Foundation Scientific Advisory Board.

“Bringing Heavy-Ion Therapy to the United States is a significant advance in treating late-stage cancers. It is the next generation in treating several cancers that we have no dependable treatment today. I enthusiastically support sending children and Veterans to see Dr. Hug in Vienna, Austria for immediate treatment. I thank Breakthrough Chronic Care for its vision and continued support.”

Robert L. Foote, MD, is Senior Resident Associate - Division of Radiation Oncology Mayo Graduate School of Medicine, Mayo Clinic College of Medicine. He serves as Chair of the Mayo Clinic Cancer Center, Rochester Cancer Practice Committee and as Chair of the Executive Committee, Department of Radiation Oncology. He is Co-Chair of the Written and Oral Examination for Head/Neck/Skin, American Board of Radiology

Contact us at www.ChronicCare.info  •  561-762-1578   •  info@ChronicCare.info

Our Mission

Breakthrough Chronic Care is a positive lifestyle company committed to significantly improve the physical, emotional and financial health of the 30 million average Americans with a chronic illness and their caregivers. Our movement is dedicated to providing superior chronic disease management and an innovative solution to eliminate up to 100% of a patient's total out-of-pocket medical costs for life. 

Terms of Use | Privacy | © 2019 Breakthrough Chronic Care. All rights reserved.